Clinical trial · Interventional
Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study concept was not approved by NCI. Study was never activated. No enrollment
Summary
Brief summary (as posted)
RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer. PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dyspnea | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Pulmonary Complications | — | UNRESOLVED | — |
| Radiation Fibrosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Losartan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Losartan Group
- description
- 50 mg Losartan tablet taken daily for 24 weeks
- interventionNames
- Drug: Losartan
Primary outcomes (1)
- measure
- Change in carbon monoxide diffusing capacity (DLCO) at 6 months
- timeFrame
- 6 months
Secondary outcomes (2)
- measure
- Feasibility of losartan potassium as treatment for radiation-induced pulmonary fibrosis
- timeFrame
- 6 months
- measure
- Pulmonary function measurements of FEV1 and FVC and dyspnea score at 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
INCLUSION CRITERIA: * At least 18 years of age or older * Diagnosed with non-small cell lung cancer stage I, II, IIIa, or IIIb * Diagnosis of radiation-induced pulmonary fibrosis (as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events \[CTCAE\] V3.0 Grade I to Grade III) and within 2 years of the last radiation therapy treatment EXCLUSION CRITERIA: * Patients with a pneumonectomy * Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker * Use of an angiotensin II receptor blocker currently or within 6 months of study entry which include: losartan, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, and telmisartan * Bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension * Patients taking lithium * Currently smoking or smoked within 6 months of study entry * Pregnant, intending to become pregnant or breastfeeding * Baseline systolic blood pressure \< 100 mmHg * History of lung transplant * History of kidney failure or liver disease * Inability to attend clinic visits
References
Publications (0)
Data not yet available